• Hero Banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Buying or Selling a Practice
Hospital Design
Leadership & Personal Growth
Personnel Management
Practice Finances
Practice Operations
Technology
Wellbeing & Lifestyle
Continuing Education
Conferences
Live Conferences
Conference News
Conference Proceedings
Resources
CBD in Pets
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

New Human Stem Cell Technology May Help Treat Canine OA

September 8, 2018
Kerry Lengyel

Results of a multicenter study show initial success in dogs with OA using a simple, cost-effective, and minimally invasive stem cell procedure created for people.

Osteoarthritis (OA) affects about 30 million US adults and an estimated 20% or more of the adult canine population. Because of the similarities between human and canine OA, investigators from Italy recently evaluated the safety, feasibility, and clinical outcomes of a stem cell treatment approved for use in human orthopedic procedures in dogs diagnosed with OA.

The treatment employs a device called Lipogems that extracts, processes, and uses a patient’s own fat tissue to provide a potential source of stem cells and growth factors to promote healing. Study findings were published in the journal Stem Cells Translational Medicine.

RELATED:

  • Cannabinoid Product Shown to Increase Comfort, Activity in Dogs With OA
  • Stem Cell Therapy in Veterinary Medicine

Study Design

In the Lipogems protocol, an animal’s own fat cells are suctioned gently from the flank and processed to screen out unwanted contaminants—creating micro-fragmented adipose tissue (MFAT). For this study, a single, intra-articular injection of MFAT was given to 130 dogs (346 joints) with spontaneous OA. The majority of dogs had grade III OA (47.7%) OA, followed by grade II (30%), grade IV (20.8%), and grade I (1.5%).

Advertisement

Clinical outcomes were determined using orthopedic examination at 2 weeks, 1, 3, and 6 months after treatment, as well as monthly pain assessments by owners for up to 24 months after treatment using the Helsinki chronic pain index.

Results

One month after treatment, 78% of the dogs showed pain reduction and improved function; after 6 months, 88% of the dogs showed improvement. Importantly, 92% of the dogs exhibited considerable or significant improvement in behavior, gait, and function after treatment.

The investigators reported that only 11% of the dogs showed no improvement compared with baseline, and only 1% of the dogs worsened.

Clinical examinations 1 month following treatment and every 3 months thereafter also confirmed there were no local or systemic short‐ or long‐term major adverse effects related to the MFAT treatment. MFAT remained in place to cushion the affected joints for up to 11 months after injection

Future Implications

According to the investigators, intra‐articular injection of autologous MFAT is a safe, feasible, and beneficial option for the treatment of canine OA.

The FDA cleared the Lipogems protocol for general use in orthopedic and arthroscopic surgery in humans in 2016, but its safety and efficacy for treating OA in humans has not yet been evaluated or confirmed by the FDA. These study findings can provide valuable One Health insight into developing successful treatment regimens for both humans and animals.


Advertisement

Latest News

This week on dvm360.com: dvm360® continues to celebrate Pride Month, and other veterinary news

3 must-sees on creating an inclusive work culture

CityVet names new chief strategy officer

Workplace bottlenecks in the LGBTQIA+ community

View More Latest News
Advertisement